1. Introduction {#sec1}
===============

*Mycobacterium tuberculosis*, the causative agent of tuberculosis (TB), latently infected one-third of the global population. TB is a global public health threat, with 10.4 million new cases and 1.7 million TB-associated deaths reported worldwide in 2016. New classes of effective anti-TB antibiotics are urgently needed \[[@B1]\] largely due to the occurrence of drug-resistant *M. tuberculosis*. Six hundred thousand new cases are rifampin resistant, including four hundred and ninety thousand patients exhibiting multidrug-resistant infection (<http://www.who.int/tb/publications/global_report/en/>). Host-directed therapy is a promising direction for the treatment of TB. Interleukin-32 (IL-32), originally called NK cell transcript 4 (NK4), can be produced by human NK and T cells stimulated with IL-2 \[[@B2]\]. IL-32 is a pleiotropic cytokine that can induce proinflammatory cytokines such as TNF-*α* and IL-1*β* via activation of NF-*κ*B and p38 MAPK signaling \[[@B3]\]. IL-32 is primarily found only in primates \[[@B3], [@B4]\]; in humans, this gene is located on chromosome 16p13.3 and consists of eight exons \[[@B3], [@B5]\]. The presence of IL-32 mRNA in both immune and nonimmune tissues and cells, including NK cells, T cells, dendritic cells, endothelial cells, and epithelial cells \[[@B6], [@B7]\], suggests that this gene has multiple functions \[[@B7]--[@B10]\], such as inflammatory response \[[@B3]\], apoptosis \[[@B11]\], cell death \[[@B12]\], differentiation \[[@B8], [@B9]\], and in the pathogenesis of inflammatory disorders, including rheumatoid arthritis \[[@B13], [@B14]\], allergic rhinitis \[[@B15], [@B16]\], neuromyelitis optica \[[@B17]\], inflammatory bowel disease \[[@B18]\], chronic rhinosinusitis \[[@B19]\], osteoporosis \[[@B20]\], atherosclerosis \[[@B21]\], cardiovascular diseases \[[@B22]\], pulmonary diseases \[[@B23]\], Crohn\'s disease \[[@B24]\], Behçet\'s disease \[[@B25]\], hidradenitis suppurativa \[[@B26]\], cancer \[[@B27]\], and myeloid leukemia \[[@B28]\]. IL-32, as a proinflammatory cytokine, has been extensively studied \[[@B29]\], and the mechanisms of action and functions of IL-32 during bacterial and viral infection as well as in cancer have been reviewed \[[@B30]--[@B32]\]. IL-32 plays protective roles in multiple infectious diseases, such as HIV \[[@B33]--[@B35]\], influenza \[[@B36]\], cytomegalovirus \[[@B37]\], HBV \[[@B38], [@B39]\], *Leishmania braziliensis* \[[@B40], [@B41]\], *Mycobacterium avium* \[[@B42]\], and *M. tuberculosis* \[[@B43], [@B44]\] infection. In this review, we highlight the immunomodulatory effects and signaling pathways of IL-32 during mycobacterial infection.

2. The Isoforms and Secretion of IL-32 {#sec2}
======================================

Many cytokines have multiple splicing isoforms. IL-17, IL-15, and vascular endothelial growth factor (VEGF) as well as IL-32 possess differently spliced isoforms. IL-15 has two alternatively spliced isoforms with identical biological properties but distinct modes of regulation and expression patterns \[[@B45]\]. There are nine alternatively spliced isoforms of IL-32 in the GenBank database (<https://www.ncbi.nlm.nih.gov/genbank/>), namely, IL-32*α*, IL-32*β*, IL-32*γ*, IL-32*δ*, IL-32*ε*, IL-32*ζ*, IL-32*η*, IL-32*θ*, and IL-32s, generated by alternative mRNA splicing \[[@B46]\]. These isoforms interact with each other to control their biological activities \[[@B46]\]. IL-32 isoforms IL-32*δ* and IL-32*β* can interact. IL-32*δ* interacts with IL-32*β* and inhibits IL-32*β*-induced production of IL-10 \[[@B47]\]. The sequence of IL-32*β* is similar to that of IL-32*γ* which is spliced into IL-32*β* in different cell lines, such as THP-1, HeLa, and human synovial fibroblast cells \[[@B48], [@B49]\]. IL-32*α* is frequently observed in the cytosol but not in the culture supernatants of epithelial cells, including primary keratinocytes, intestinal epithelial cell lines, and colonic subepithelial myofibroblasts \[[@B18], [@B50], [@B51]\]. IL-32*α* specifically binds to proteinase-3 with high affinity, and this binding is independent of enzyme activity \[[@B52]\]. IL-32*α* has been reported to interact with PKC*ε* and STAT3 \[[@B53]\] and with focal adhesion kinase 1 (FAK1) and integrins \[[@B54]\]. IL-32*β* and IL-32*γ* can induce caspase-8- and caspase-3-dependent apoptosis \[[@B54], [@B55]\]. IL-32*β* interacts with C/EBP*α* and PKC*δ*, culminating in increased IL-10 production \[[@B56]\]. IL-32*γ*, without exon deletions, is the most active isoform \[[@B46], [@B57]\].

The secretion of IL-32 isoforms remains to be investigated. IL-32*γ* possesses an N-terminal hydrophobic signal peptide, which is a typical feature of secreted cytokines. IL-32 is expressed in peripheral blood mononuclear cells (PBMCs) by LPS stimulation or *M. tuberculosis* infection, instead of *Staphylococcus aureus* and *Candida albicans* \[[@B58]\]. The IL-32*α* isoform was detected as an intracellular fraction, whereas the IL-32*β* isoform was found in the cell culture supernatant of Cos7 cells under transient transfection \[[@B3]\]. However, when performing transient transfection of IL-32*β* into bovine aortic vascular endothelial cells (BAVECs), IL-32*β* was found mainly in the cytosol and localized in the endoplasmic reticulum \[[@B6]\]. In addition, IL-32*β* was detected in the supernatant derived from the cytoplasm of apoptotic T cells but not secreted in anti-CD3 antibody-activated human T cells \[[@B12]\]. However, IL-32 can bind to the RGD motif of integrin, and IL-32 isoforms contain predicted tyrosine sulfation sites, which are prevalent in secreted proteins \[[@B2], [@B5], [@B59]\]. In HT-29 cells stimulated with TNF-*α* and IFN-*γ*, IL-32 was associated with membrane vesicles, and the release of IL-32 depended on exosome-like vesicle release mechanisms \[[@B60]\]. Therefore, IL-32 may be secreted via a nonclassical protein secretion pathway, similar to IL-33 and HMGB1, without typical signal peptides and are released via ER/Golgi-independent means \[[@B60], [@B61]\].

3. The Cellular Source and Expression of IL-32 {#sec3}
==============================================

IL-32 does not share homology with known cytokines. IL-32 expression has been detected in multiple human tissues and organs, including spleen, thymus, leukocytes, lungs, heart, placenta, liver, muscle, kidneys, pancreas, prostate, small intestine, colon, and brain \[[@B3]\]. The IL-32 mRNA is highly expressed in immune cells, and IL-32 expression has also been detected in nonimmune tissues and cells \[[@B6], [@B55], [@B62]\]. NK cells \[[@B2], [@B3], [@B63]\], monocytes/macrophages \[[@B3], [@B62], [@B64]\], dendritic cells (DCs) from PBMCs \[[@B58], [@B62], [@B65]\], neutrophils \[[@B66]\], T lymphocytes \[[@B62]\], epithelial cells \[[@B67]\], endothelial cells \[[@B68]\], fibroblasts \[[@B69]\], and hepatocytes \[[@B64]\] can express IL-32. IL-32 is also expressed and released in both cancer and noncancer cell lines, including the HepG2 human cancer cell line \[[@B3], [@B70]\], A549 cells \[[@B71], [@B72]\], pancreatic cancer cell lines such as MIA PaCa-2, PANC-1, and BxPC-3 \[[@B73], [@B74]\], the human hepatoma cell line Huh-7.5 \[[@B64]\], cervical cancer cells and tissues \[[@B75]\], the HEK293T cell line \[[@B34], [@B57]\], the HT-29 human colon cell line \[[@B60]\], the human colon neuroendocrine LCC-18 cell line \[[@B34]\], human colonic subepithelial myofibroblasts \[[@B51]\], human primary keratinocytes \[[@B50]\], synovial cells and fibroblast-like synoviocytes (FLS) \[[@B14], [@B69]\], and the marrow stromal cell lines HS-5 and HS-27A \[[@B76]\].

Four major isoforms (IL-32*α*, IL-32*β*, IL-32*γ*, and IL-32*δ*) were found in IL-2-stimulated human NK cells \[[@B3]\]. IL-32*β*, IL-32*ε*, and IL-32*ζ* were isolated from activated T cells \[[@B12]\], and IL-32s expression was first observed in Jurkat human leukemia T cells \[[@B70]\]. IL-32*ε*, IL-32*ζ*, IL-32*θ*, and IL-32s are also found in T cells, and the IL-32*β* isoform is mainly expressed in activated T cells \[[@B2], [@B12], [@B46]\]. IL-32*θ* and IL-32s were identified from monocyte-derived dendritic cells purified from human PBMCs and Jurkat T cells via 5′ RACE \[[@B46]\]. The function of different IL-32 isoforms in different cell types was summarized in [Table 1](#tab1){ref-type="table"}. IL-32 mRNA levels increased after stimulation with Con A and monoclonal antibodies against CD3 and CD28 \[[@B62]\]. TNF-*α* reciprocally induced the expression of IL-32 mRNA in monocyte-derived dendritic cells, T cells, and synovial fibroblasts \[[@B62]\]. Intracellular IL-32 is constitutively expressed in human umbilical vein endothelial cells (HUVECs). The IL-32*α* and IL-32*γ* isoforms are the most prominently expressed IL-32 mRNAs in unstimulated endothelial cells \[[@B6], [@B60], [@B68], [@B77]\], while TNF-*α* and IL-1*β* induced the expression of IL-32*β* in endothelial cells \[[@B4]\]. Studies have shown that GM-CSF induces the expression of the IL-32*α*, IL-32*β*, IL-32*γ*, and IL-32*δ* isoforms in a caspase-1-dependent manner in eosinophils \[[@B15], [@B16]\]. Synovial fibroblasts isolated from patients with rheumatoid arthritis express IL-32*γ* after stimulation with IL-1*β* and TNF-*α* \[[@B48]\]. TNF-*α* can also promote the expression of the IL-32*α*, IL-32*β*, IL-32*δ*, and IL-32*γ* isoforms by activating the Syk/PKC*δ*/JNK/c-Jun signaling pathway \[[@B69]\]. The cell or tissue-specific expression patterns and functions of each isoform of IL-32 remain to be determined.

4. The Function of IL-32 in the Activation of Signaling Pathways {#sec4}
================================================================

Although proinflammatory activities are key features of IL-32 and are enhanced by the different IL-32 isoforms, which induce the expression of cytokines such as TNF-*α* \[[@B3]\], IL-1*β* \[[@B87]\], IL-6 \[[@B53]\], IL-8 \[[@B88]\], and COX-2 \[[@B75]\], the mechanism of IL-32-based signaling remains unknown. The potential signaling pathways of macrophages induced by IL-32 are summarized in [Figure 1](#fig1){ref-type="fig"}. IL-32*α*, IL-32*β*, and IL-32*γ* are the main isoforms of IL-32 and have been shown to enhance the inflammatory response, suggesting that IL-32 can mediate diverse responses by interacting with different signaling molecules \[[@B53], [@B54], [@B56]\]. Intracellular IL-32*α* interacts with PKC*ε* and STAT3, leading to phosphorylation of STAT3 and induction of IL-6 production after PMA stimulation \[[@B53]\]. Induction of TNF-*α* by IL-32*α* is mediated by phosphorylation of inhibitor kappaB (IkB) and ERK1/2 \[[@B89]\], NF-*κ*B activation, and p38 MAPK phosphorylation in macrophage cell lines such as THP-1 and RAW264.7 \[[@B3]\]. Both IL-32*α* and IL-32*β* induce the expression of TNF-*α*, IL-8, and CXCL2 in THP-1 and RAW264.7 cells \[[@B3], [@B62]\] and induce the expression of TNF-*α* and CXCL2 in peritoneal murine macrophages \[[@B57]\]. Treatment of THP-1 cells with IL-32*γ* induced TNF-*α*, IL-6, IL-1*β*, and IL-8 expression via activation of the p38, caspase-1, and NF-*κ*B pathways \[[@B16]\]. In addition, IL-32*γ*-stimulated monocytes and macrophages, such as THP-1-derived macrophages and monocyte-derived macrophages, induce the expression of TNF-*α*, IL-1*β*, IL-6, CXCL1, and CXCL2 along with IL-1Ra and IL-10 via the ERK1/2 and Akt signaling pathways \[[@B80]\]. Moreover, IL-32*γ* triggers the production of TNF-*α*, IL-1*β*, IL-23, CXCL1, and CXCL8 via the PI3K/Akt/P300/NF-*κ*B signaling pathway \[[@B81]\]. PR3 cleaves IL-32*α* and increases the activity of IL-32, which subsequently activates PAR2 and triggers the TRIF and Ras/Raf pathways, resulting in increased type I IFN (IFN-*α* and IFN-*β*) and TNF-*α* production \[[@B90]\]. However, IL-32 isoforms can reduce cellular inflammation \[[@B47], [@B65]\]. IL-32*δ* inhibits the binding of IL-32*β* to PKC*δ*, resulting in decreased IL-10 production \[[@B47]\]. In monocyte-derived DCs and human macrophages, endogenous IL-32*β* promotes IL-10 expression, resulting in decreased expression of proinflammatory cytokines, such as IL-12, TNF-*α*, and IL-1*β* \[[@B65]\]. IL-32*β* promotes IL-10 production via interaction with PKC*δ*, which phosphorylates C/EBPa, an inhibitor that binds to the IL-10 promoter \[[@B56]\]. Moreover, low-severity arthritis was observed in a human IL-32*β* transgenic mouse model \[[@B91]\]. In summary, IL-32 regulates the expression of inflammatory cytokines.

5. IL-32 Regulates the Expression of MicroRNAs {#sec5}
==============================================

IL-32 isoforms were shown to induce inflammation by regulating the expression of microRNAs \[[@B20], [@B37], [@B92], [@B93]\]. The expression of IL-32 is activated by human cytomegalovirus infection and functionally downregulated by hcmv-miR-UL112-1 \[[@B37]\]. MiR-23b-3p directly targets and induces the expression of PTEN, resulting in reduction in PI3-kinase, total Akt, and IL-32 levels \[[@B93]\]. IL-32*α* promotes the expression of the atheroprotective-associated genes Timp3 and Reck by downregulating the Rprd2-Dgcr8/Ddx5-Dicer1 biogenesis axis downstream of microRNA-205 \[[@B92]\]. Overexpression of human IL-32*γ* in transgenic mice led to increased bone formation, reduced bone loss with advancing age, and high osteogenic capacity of osteoblasts by upregulation of microRNA-29*α* \[[@B20]\]. Therefore, IL-32 is a novel protective cytokine that acts against mycobacterial infection. Elucidating the complex interactions between the IL-32 isoforms, microRNA-based regulation of the isoforms and the function of IL-32 will provide novel insight into the novel mechanism of the protective roles of IL-32 in multiple diseases.

6. The Function of IL-32 in Mycobacterial Infection {#sec6}
===================================================

*M. tuberculosis*, the causative agent of human TB, can subvert host immune defenses to promote its own intracellular survival. Infection of human macrophages or PBMCs with *M. tuberculosis* H37Rv induced IL-32 production \[[@B11], [@B58]\], suggesting a role for IL-32 in the control of *M. tuberculosis* infection. *M. tuberculosis* and *Mycobacterium bovis* induced the release of IL-32 from PBMCs via IFN-*γ*, which was produced after caspase-1-activated IL-18 release \[[@B58]\]. Silencing of endogenous IL-32 in differentiated THP-1 human macrophages significantly decreased TNF-*α*, IL-1*β*, and IL-8 production and simultaneously increased the *M. tuberculosis* burden in infected macrophages \[[@B11]\].

The antimycobacterial effect of IL-32 may be partly due to enhanced cell apoptosis in infected macrophages. IL-32*γ* is a potent inducer of apoptosis; both IL-32*γ* and IL-32*β* can induce caspase-3- and caspase-8-dependent apoptosis \[[@B12], [@B27]\]. Endogenous IL-32 mediated *M. tuberculosis*-induced apoptosis of macrophages, suggesting that apoptosis of infected macrophages is a mechanism to protect against mycobacterial infection. IL-32*γ* decreased the *M. tuberculosis* burden within macrophages via classic caspase-3-mediated apoptosis \[[@B11]\] and caspase-1- or lysosomal-cathepsin-mediated apoptosis \[[@B94]\]. Our previous study showed that *M. tuberculosis* PE/PPE (Pro(P)-Glu(E) and Pro(P)-Pro(P)-Glu(E)) family antigen PPE32 induced ER-stress-mediated cell apoptosis via the stimulation of IL-32 production \[[@B95]\]. In addition, IL-32 serves as a mediator of IFN*γ*-vitamin D-related antimicrobial activity and a marker for latent TB infection (LTBI), as determined via the mining of TB transcriptomic datasets \[[@B96]\]. IL-32*γ* was also found to be associated with the vitamin D antimicrobial pathway in human macrophages \[[@B84]\]. IFN-*γ*-induced IL-32*γ* increases the expression of the vitamin D receptor, leading to the expression of cathelicidin and *β*-defensin 2 (DEFB4), which are potent antimicrobial peptides that act against intracellular infection in macrophages \[[@B84]\]. IFN-*γ* treatment activates the production of NO in macrophages, which is the main microbicidal molecule involved in the control of *M. tuberculosis* infection \[[@B97]\]. Human THP-1 cells express iNOS and produce NO after differentiation into macrophages by treatment with IL-32*γ* \[[@B98]\]. The production of reactive oxygen species (ROS) is required to induce the microbicidal activity mediated by vitamin D and cathelicidin, and cathelicidin enhances the production of ROS and proinflammatory cytokines, such as TNF-*α*, IL-8, and IL-6 \[[@B99]\]. *M. tuberculosis*-induced GM-CSF can promote NO production and phagolysosomal fusion against *M. tuberculosis* infection \[[@B100], [@B101]\]. GM-CSF might kill intracellular *M. tuberculosis* via induction of IL-32 as GM-CSF increases the expression of IL-32 in other cell types \[[@B15], [@B16]\]. In summary, IL-32*γ* is a protective molecule that enhances the microbicidal activity of macrophages against *M. tuberculosis* via increased apoptosis and pyroptosis, and antimicrobial peptides induced by vitamin D and GM-CSF are involved in protection against *M. tuberculosis* infection ([Figure 1](#fig1){ref-type="fig"}).

IL-32, lacking sequence homology with known cytokine families, is a novel proinflammatory cytokine \[[@B3]\]. The expression of IL-32 was increased in patients with *M. avium* infection \[[@B42]\]. IL-32*γ* significantly reduced the intracellular survival of *M. avium* in human monocyte-derived macrophages \[[@B42]\]. Moreover, the expression of endogenous IL-32 and NOD2 was increased in patients with the restrictive tuberculoid form of leprosy, which is caused by *Mycobacterium leprae* infection \[[@B102]\], suggesting that both NOD2 and IL-32 are associated with leprosy. IL-32 expression was increased in surgically resected lungs of active TB patients, particularly in airway epithelial cells and granuloma macrophages \[[@B43]\], suggesting a protective role of IL-32 against *in vivo M. tuberculosis* infection. However, there was a decrease in the protective response of IL-32*γ* against *M. tuberculosis* at later time points of infection as IL-32*γ* mRNA is spliced into IL-32*β*, leading to increased levels of IL-10-expressing macrophages or DCs in the lungs \[[@B43]\].

This work was supported by the National Natural Science Foundation (81701979, 81371851, 81071316 and 81601740), the general program of Chongqing Science and Technology Commission (cstc2017jcyjA0560), the Venture & Innovation Support Program for Chongqing Overseas Returnees (cx2017106), the National Megaprojects for Key Infectious Diseases (2008ZX10003-006 and 2008ZX10003-001), the Applied Basic Research Program of Science & Technology Department of Sichuan Province (2018JY0108), and the Doctoral Scientific Research Foundation of Neijiang Normal University.

Conflicts of Interest
=====================

The authors declare that they have no competing interests.

![Endogenous IL-32-induced signaling pathway activation in macrophages and the potential roles of this pathway in *M. tuberculosis* infection.](JIR2018-1535194.001){#fig1}

###### 

The function of IL-32 isoforms in different cell type.

  Cell type                                                          IL-32 isoform      Targets                                                             Function                                                Reference
  ------------------------------------------------------------------ ------------------ ------------------------------------------------------------------- ------------------------------------------------------- --------------------
  U937 and monocyte-derived DCs                                      IL-32*β*           Increase in IL-10 production                                        Anti-inflammatory effects                               \[[@B65]\]
  Tumor cells                                                        IL-32*β*           Decrease IL-1*β*, IL-6, TNF-*α*, and increase IL-10 production      Tumor growth                                            \[[@B78]\]
  Myeloid cells and U937 cells                                       IL-32*β*           Increase in IL-10 production                                        Anti-inflammatory effects                               \[[@B56]\]
  Eosinophils                                                        IL-32*γ*           Induces production of IL-6, TNF-*α*, IL-8, and VEGF                 Inflammation of allergic rhinitis                       \[[@B15]\]
  Eosinophils                                                        IL-32*γ*           Induces IL-1*β*, TNF-*α*, CXCL8, CCL3, CCL4, CD18, and ICAM-1       Interacts with NOD1 or NOD2; PR3 activation             \[[@B79]\]
  Monocytes or monocyte-derived macrophages                          IL-32*γ*           TNF-a, IL-1b, IL-6, GROa/CXCL1, and MCP-1/CCL2, IL-10, and IL-1ra   Activation of ERK1/2, Akt, and Fyn signaling pathways   \[[@B80]\]
  PBMC                                                               IL-32*α*/*β*       TNF-*α*, IL-6                                                       ---                                                     \[[@B57]\]
  Murine macrophage                                                  IL-32*α*/*β*       TNF-*α*, CXCL2                                                      ---                                                     
  THP-1 and RAW264.7                                                 IL-32*α*/*β*       TNF-*α*, IL-8, and, CXCL2                                           ---                                                     \[[@B3], [@B62]\]
  THP-1 cells                                                        IL-32*γ*           Induces TNF-a, IL-1b, IL-8, and IL-6                                Activation of p38, caspase-1 and NF-*κ*B pathways       \[[@B16]\]
  THP-1 cells                                                        IL-32*γ*           TNF-*α*, IL-23, CXCL1, CXCL8, and IL-1*β*                           PI3K/Akt/P300/NF-*κ*B signaling pathways                \[[@B81]\]
  Endothelial cells                                                  IL-32*α*/*β*/*ε*   ICAM-1, IL-1*α*, IL-8, and IL-6                                     Vascular inflammation                                   \[[@B68]\]
  PBMC/precursors                                                    IL-32*α*           Activates Akt, JNK, ERK1/2, and NF-*κ*B pathways                    Cell differentiation                                    \[[@B10]\]
  Murine DC                                                          IL-32*γ*           Suppresses the production of CCL5                                   Driving acquired immunity                               \[[@B82]\]
  Murine bone marrow--derived DCs                                    IL-32*γ*           IL-6 and IL-12                                                      Driving acquired immunity                               \[[@B83]\]
  PBMCs, CD4^+^ T cells, CD163^+^ macrophages, Treg cells, and DCs   IL-32*γ*           IDO and ILT4                                                        Immunosuppression                                       \[[@B35]\]
  Monocyte-derived macrophages                                       IL-32*γ*           Induce cathelicidin and *β*-defensin 2 (DEFB4)                      Microbicidal activity                                   \[[@B84]\]
  PBMC                                                               IL-32*γ*           IFN*λ*1                                                             Antiviral activity                                      \[[@B85]\]
  T cells, epithelial cells, THP-1, and tumor cells                  IL-32*γ*/*β*       Caspase-3, Caspase-8                                                Cell apoptosis                                          \[[@B12], [@B27]\]
  THP-1 cells                                                        IL-32*θ*           Suppresses the production of CCL5                                   Modulators of inflammation                              \[[@B86]\]
  THP-1 cells                                                        IL-32*θ*           Decreases TNF-*α*                                                   p38 and NF-*κ*B signaling pathways                      \[[@B28]\]
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